- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Anti-PD-1 Treatment Selection
During this segment, Richard W. Joseph, MD, describes the effectiveness of the anti-PD-1 agents pembrolizumab and nivolumab, and discusses similarities and differences between the 2 drugs.
Dr Joseph explains that although no head-to-head trials have directly compared the 2 agents, cross-trial comparisons have demonstrated that they are similar in terms of safety and efficacy. For this reason, he questions why the FDA approved pembrolizumab after just a phase 1 study but required a phase 3 study prior to approving nivolumab.
One difference between the 2 drugs, he notes, is that while nivolumab is administered every 2 weeks, pembrolizumab is given every 3 weeks.
Dr Joseph suggests that unless proved otherwise, the agents should be considered equivalent by managed care organizations and payer coverage should be the same for both drugs.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
